2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Specimen Handling
288
Magnetic Resonance Spectroscopy
238
pembrolizumab
228
Carboplatin
187
Cisplatin
153
Biopsy
151
Cyclophosphamide
144
Paclitaxel
133
Nivolumab
123
Gemcitabine
113
Bevacizumab
106
Radiotherapy
96
Dexamethasone
86
Pemetrexed
83
fludarabine
78
Fluorouracil
76
Doxorubicin
76
Docetaxel
76
atezolizumab
73
Radiation
72
Leucovorin
70
Rituximab
68
Oxaliplatin
66
venetoclax
61
durvalumab
61
Prednisone
61
Vincristine
56
Cetuximab
56
Lenalidomide
55
Etoposide
54
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Adrenal Cortex Hormones
×
30 days
×
Clear all
NCT06925737
2026-05-29
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,440 enrolled
NCT06780085
2026-05-26
MK-3475-01H
Merck Sharp & Dohme LLC
Phase 2
Recruiting
96 enrolled